Skip to main content

Table 1 Patient eligibility criteria

From: TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial

Inclusion criteria
• Written informed consent
• Infra-renal AAA with maximum orthogonal diameter of ≥35 mm and ≤49 mm on CTA or ultrasound
• No current indication for AAA repair, or expectation that this will be revised in 12 months
• Likely to comply with treatment over 24 months, including seven visits to study centre
Exclusion criteria
• Currently taking or likely to start taking an AT1 blocker
• Currently taking or likely to start taking an ACE inhibitor
• Previous abdominal aortic surgery
• Contraindication to telmisartan:
o Renal impairment: creatinine >1.5 x ULN
o Known renal artery stenosis >70 % of one or both renal arteries
o Chronic liver disease (that is, cirrhosis or hepatitis) or abnormal liver function (that is, ALT > 1.5 x ULN)
o Electrolyte imbalance
o Active gout
  1. AAA, abdominal aortic aneurysm; ACE, angiotensin converting enzyme; ALT, alanine transaminase; AT1, angiotensin II receptor type 1; CTA, computed tomographic angiography; ULN, upper limit of normal